<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05624983</url>
  </required_header>
  <id_info>
    <org_study_id>RBHP 2022 SARRET</org_study_id>
    <nct_id>NCT05624983</nct_id>
  </id_info>
  <brief_title>Exploration of High Frequency Otoacoustic Emissions and Developmental Language Disorders</brief_title>
  <acronym>OTOEMHF</acronym>
  <official_title>Exploration of High Frequency Otoacoustic Emissions and Developmental Language Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Among the objective non-invasive audiological explorations the distorsion products of&#xD;
      otoacoustic emissions (DPOAE) allow to quickly assess the function of the cochlear outer hair&#xD;
      cells (without the active participation of the subject). This technique is used in newborn&#xD;
      screening. While humans are able to perceive sounds in a frequency range of 20Hz to 20kHz,&#xD;
      routine clinical audiological assessment is only concerned with frequencies between 1-4kHz.&#xD;
&#xD;
      This obscures the importance of high frequencies (HF) which can be easily assessed by DPOAEs.&#xD;
      In young children, the perception of these high frequencies could also play an important role&#xD;
      in language acquisition.&#xD;
&#xD;
      The main objective of this study is to evaluate the relationship between subtle&#xD;
      high-frequency hearing impairment, as assessed by the DPOAE (non-invasive, rapid and simple&#xD;
      audiological test), and language delay or difficulties in a pre-, peri- and school-age&#xD;
      pediatric population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2023</start_date>
  <completion_date type="Anticipated">July 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>one group of cases (children with language disorder) one group of control (children without language disorder)</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HF DPOAE measurement</measure>
    <time_frame>Day 1</time_frame>
    <description>at frequencies 4265, 4688, 5154, 5666, 6229, 6847, 7527, 8275, 9096 and 10000 Hz</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence or absence of HF DPOAE</measure>
    <time_frame>Day 1</time_frame>
    <description>assessed by tympanometry, categorisation of this categorisation of this into 3 classes A, B and C frequency will be defined by a signal to noise ratio &gt; 6 dB. The absence of DPOAE for each frequency will be defined by a signal to noise ratio ≤ 6 dB.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional status of the middle ear</measure>
    <time_frame>Day 1</time_frame>
    <description>assessed by tympanometry, categorisation of this categorisation of this into 3 classes A, B and C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of the average hearing loss (baseline pure tone audiometry)</measure>
    <time_frame>Day 1</time_frame>
    <description>according to the BIAP, average of audiometric thresholds at 500Hz thresholds at 500Hz, 1kHz, 2kHz and 4kHz</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laterality of hearing loss at the DPOAE level with a classification into 3 groups</measure>
    <time_frame>Day 1</time_frame>
    <description>Not affected bilaterally affected, unilateral affected, bilateral affected; one side is considered to be affected if at least one of the at least one of the HF DPOAEs is ≤ 6 dB.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity and type of language impairment assessed by the EVALO/ EVALEO</measure>
    <time_frame>day 1</time_frame>
    <description>assessment and scoring by speech and language therapists</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">138</enrollment>
  <condition>Language Development Disorders</condition>
  <arm_group>
    <arm_group_label>Case group (children with language disorder)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hearing diagnostic test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>controle group (children without language disorder)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Hearing diagnostic test</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>acoustic otoemisions</intervention_name>
    <description>TOAE and DPOAE</description>
    <arm_group_label>Case group (children with language disorder)</arm_group_label>
    <arm_group_label>controle group (children without language disorder)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Otoscopy</intervention_name>
    <description>presence of earwax checked by video otoscop</description>
    <arm_group_label>Case group (children with language disorder)</arm_group_label>
    <arm_group_label>controle group (children without language disorder)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Audiometry</intervention_name>
    <description>Hearing Threshold will be measured with the AD528 interacoustics</description>
    <arm_group_label>Case group (children with language disorder)</arm_group_label>
    <arm_group_label>controle group (children without language disorder)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Tympanometry</intervention_name>
    <description>Tympanic mobility will be measyred with the Titan interacoustics</description>
    <arm_group_label>Case group (children with language disorder)</arm_group_label>
    <arm_group_label>controle group (children without language disorder)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for case (children with language disorder):&#xD;
&#xD;
          -  Normal hearing (after an audiometry test, even if an ENT consultation has been carried&#xD;
             out beforehand and if the doctor has not found any hearing problem, as defined in the&#xD;
             NF EN ISO 70292017-04 standard, and according to an average hearing loss calculated&#xD;
             according to the BIAP &lt;20dB HL)&#xD;
&#xD;
          -  Free and informed consent of the parental authority and the patient&#xD;
&#xD;
          -  Affiliated to the social security system&#xD;
&#xD;
          -  Presenting a developmental language acquisition disorder (score according to the EVALO&#xD;
             / EVALEO test)&#xD;
&#xD;
          -  For children between 15 and 17 years of age, completion of the EVALEO test before&#xD;
             their 16th birthday&#xD;
&#xD;
        Inclusion Criteria for control (children without language disorder) :&#xD;
&#xD;
          -  Normal hearing (after an audiometry test, even if an ENT consultation has been&#xD;
             performed beforehand and if the doctor has not found any hearing problem, as defined&#xD;
             in the NF EN ISO 70292017-04 standard, and according to an average hearing loss&#xD;
             calculated according to the BIAP &lt;20dB HL)&#xD;
&#xD;
          -  Free and informed consent of the parental authority and the patient&#xD;
&#xD;
          -  Enrolled in the social security system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hearing disorder identified during the inclusion visit (presence of cerumen or foreign&#xD;
             body in the earwax plug or foreign body in the external auditory canal, tympanometry&#xD;
             suggesting a middle ear disorder, audiometry with thresholds outside the normal&#xD;
             thresholds outside the normal range (0-20dB HL), absence of responses in (0-20dB HL),&#xD;
             absence of responses in acoustic otoemissions or acoustic distortion products) on&#xD;
             conversational frequencies between 500Hz and 4kHz.&#xD;
&#xD;
          -  Declaration by the parents of an ENT follow-up for a hearing disorder and/or a speech&#xD;
             therapy for a language disorder&#xD;
&#xD;
          -  Refusal of participation evoked by the subject&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lise Laclautre</last_name>
    <phone>04 73 75 11 95</phone>
    <email>promo_interne_drci@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand, UMR INSERM 1107</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Lise Laclautre</last_name>
      <phone>04 73 75 11 95</phone>
      <email>promo_interne_drci@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Catherine SARRET</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabrice GIRAUDET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2022</verification_date>
  <study_first_submitted>November 2, 2022</study_first_submitted>
  <study_first_submitted_qc>November 21, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2022</study_first_posted>
  <last_update_submitted>November 21, 2022</last_update_submitted>
  <last_update_submitted_qc>November 21, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Language development disorders</keyword>
  <keyword>otoemisions</keyword>
  <keyword>child</keyword>
  <keyword>high frequencies</keyword>
  <keyword>hearing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Language Disorders</mesh_term>
    <mesh_term>Language Development Disorders</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

